Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference

May 09, 2018   |   
I Care 0 Cares

LONDON, UK – May 9, 2018 – Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will present data from its chronic obstructive pulmonary disease (COPD) clinical trial program with lead product candidate, RPL554, at the American Thoracic Society International Conference (ATS) in San Diego, CA from May 18-23, 2018.

RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as bronchodilator properties, and is currently in development for the maintenance treatment of COPD and for the treatment of cystic fibrosis.

Details of the Company’s poster presentations are listed below and the abstracts are available to the public online at the American Thoracic Society website.

Rapid Abstract Poster Discussion Session (Abstract 4227, Poster 9964): RPL554, A First-In-Class Dual PDE3/4 Inhibitor, Causes Rapid Additional Bronchodilation When Dosed with Tiotropium in COPD Patients
Session Title: Clinical Trials and Studies in COPD (B102)
Date and Time: Monday, May 21, 2018; 2:15 PM - 4:15 PM PDT
Location: San Diego Convention Center, Room 30 C-E (Upper Level)

Thematic Poster Session (Abstract 3022, Poster 9880): Low Oral Bioavailability of RPL554, a First-in-Class Dual PDE3/4 Inhibitor, Demonstrates that Its Nebulized, Inhaled Formulation Is Appropriate for Delivering Optimal Pulmonary Dose
Session Title: COPD: Maintenance Therapy (B33)
Date and Time: Monday, May 21, 2018; 9:15 AM - 4:15 PM PDT
Location: San Diego Convention Center, Area L (Hall A-B2, Ground Level)

Join Us on COPD360social

Sign In to Participate
Or register to become a member